BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3043151)

  • 1. Therapeutic effects of organic germanium.
    Goodman S
    Med Hypotheses; 1988 Jul; 26(3):207-15. PubMed ID: 3043151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of spirogermanium in advanced ovarian carcinoma.
    Brenner DE; Jones HW; Rosenshein NB; Forastiere A; Dillon M; Grumbine F; Tipping S; Burnett L; Greco FA; Wiernik PH
    Cancer Treat Rep; 1983 Feb; 67(2):193-4. PubMed ID: 6825131
    [No Abstract]   [Full Text] [Related]  

  • 3. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Saul PB; Copeland LJ; Gershenson DM; Krakoff IH
    Cancer Treat Rep; 1985 Jan; 69(1):139-40. PubMed ID: 3967257
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary.
    Weiselberg L; Budman DR; Schulman P; Vinciguerra V; Degnan TJ; Pasmantier M
    Cancer Treat Rep; 1982 Aug; 66(8):1675-6. PubMed ID: 7201885
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of spirogermanium in advanced (extensive) non-small cell lung cancer.
    Dhingra HM; Umsawasdi T; Chiuten DF; Murphy WK; Holoye PY; Spitzer G; Valdivieso M
    Cancer Treat Rep; 1986 May; 70(5):673-4. PubMed ID: 3708617
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of spirogermanium in advanced ovarian malignancy.
    Tropé C; Mattsson W; Gynning I; Johnsson JE; Sigurdsson K; Orbert B
    Cancer Treat Rep; 1981; 65(1-2):119-20. PubMed ID: 6261944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of spirogermanium in metastatic prostate cancer.
    Dexeus FH; Logothetis C; Samuels ML; Hossan B
    Cancer Treat Rep; 1986 Sep; 70(9):1129-30. PubMed ID: 3742495
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of spirogermanium in advanced breast cancer.
    Kuebler JP; Tormey DC; Harper GR; Chang YC; Khandekar JD; Falkson G
    Cancer Treat Rep; 1984 Dec; 68(12):1515-6. PubMed ID: 6509457
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.
    Budman DR; Ginsberg S; Perry M; Weinberg V; Schein P; Hanson J; Coleman M; Wood W
    Cancer Treat Rep; 1982 Aug; 66(8):1667-8. PubMed ID: 7105058
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
    Schulman P; Davis RB; Rafla S; Green M; Henderson E
    Cancer Treat Rep; 1984 Oct; 68(10):1305-6. PubMed ID: 6525606
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of spirogermanium for treatment of advanced breast cancer.
    Falkson G; Falkson HC
    Cancer Treat Rep; 1983 Feb; 67(2):189-90. PubMed ID: 6825129
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of spirogermanium in the treatment of metastatic breast cancer.
    Pinnamaneni K; Yap HY; Legha SS; Blumenschein GR; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1197-8. PubMed ID: 6478457
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I clinical trial of spirogermanium.
    Schein PS; Slavik M; Smythe T; Hoth D; Smith F; Macdonald JS; Woolley PV
    Cancer Treat Rep; 1980; 64(10-11):1051-6. PubMed ID: 7459890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
    Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG; Ruckdeschel JC
    Med Pediatr Oncol; 1989; 17(3):197-201. PubMed ID: 2546026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma.
    Boros L; Tsiatis AA; Neiman RS; Mann RB; Glick JH
    Cancer Treat Rep; 1986 Jul; 70(7):917-8. PubMed ID: 3719586
    [No Abstract]   [Full Text] [Related]  

  • 16. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
    Invest New Drugs; 1985; 3(3):307-10. PubMed ID: 4066225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer E; Kerr I; Bodurtha A; Iscoe N; McCulloch P; Pritchard K; Quirt I
    Invest New Drugs; 1985; 3(3):303-5. PubMed ID: 4066224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of spirogermanium in advanced human malignancy.
    Vogelzang NJ; Gesme DH; Kennedy BJ
    Am J Clin Oncol; 1985 Aug; 8(4):341-4. PubMed ID: 3909806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Organic germanium: its toxic effect and function in medical care].
    Kong X
    Zhonghua Yi Xue Za Zhi; 1993 Aug; 73(8):454-6. PubMed ID: 8111643
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.